Ulocuplumab

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL) . Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models[1][2].

Product Specifications

CAS Number

[1375830-34-4]

Product Name Alternative

BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

UNSPSC

12352203

Target

CXCR

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/ulocuplumab.html

Purity

99.90

Solubility

10 mM in DMSO

Smiles

[Ulocuplumab]

Molecular Weight

(144.84 kDa)

References & Citations

[1]Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338) : a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7 (3) :2809-22. |[2]Kuhne MR, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19 (2) :357-66.